Mark joined Catamaran as Chief Operating Officer in March 2020. He brings more than twenty-five years of experience in the biotechnology industry—spanning operations, legal affairs and busines development. Most recently, he served as Vice President, Legal Affairs of Rubius Therapeutics where he founded and built the legal department and led all internal legal activities supporting Rubius’ rapid growth to a clinical-stage, cell therapy company and its IPO. Prior to Rubius, Mark served as a business and legal advisor to several early-stage, venture-backed biotechnology companies, including senior roles at cell therapy and gene therapy companies. Previously in his career, he served as Associate General Counsel of Millennium Pharmaceuticals (now Takeda Oncology) where he founded and built the legal department and led internal legal activities, including playing instrumental roles in negotiating several major pharmaceutical partnerships and executing the company’s IPO. Prior to Millennium, Mark was Chief Patent Counsel for Repligen Corporation. He began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). Mark holds a JD from Northeastern University School of Law and a BS in Biology from Tufts University.